@miapi , can I just sat that your Doctor is misinterpreting the cancer risk. Cladribine was initially discounted as an MS therapy, due to the isolated diagnosis of cancer in the clinical trials.
It was only when the Trials data was reviewed that Cladribine was not seen as being the cause. It was then down to some pioneering off-label usage that gained enough momentum to have the trials data fully reviewed, with Cladribine becoming an approved treatment under the label, Mavenclad.
The argument that the hospital has no experience isn’t that strong. Cladribine is administered orally, so no infusion routines to be considered. And, it does pose the question about how hospitals gain experience in a new drug………
The bottom line is that it’s your body. Surely you should have a say in what goes into it!